Literature DB >> 20007673

Impact of improved classification on the association of human papillomavirus with cervical precancer.

Philip E Castle1, Mark Schiffman, Cosette M Wheeler, Nicolas Wentzensen, Patti E Gravitt.   

Abstract

Misclassification of exposure and surrogate endpoints of disease can obscure causal relations. Using data from the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS, 1997-2001), the authors explored the impact of exposure (human papillomavirus (HPV) detection) and endpoint (histologic cervical precancer) classification on their mutual association. Women referred into this study with an atypical squamous cells of undetermined significance Papanicolaou test with satisfactory results for all 4 HPV tests were included in this analysis (n = 3,215; 92.2%). HPV testing results were related to different definitions of cervical precancer, based on paired, worst 2-year histologic diagnoses, by calculating clinical sensitivity, specificity, and odds ratios. The authors found that HPV test sensitivity increased and specificity decreased with increasing certainty of cervical precancer, with HPV testing having the highest sensitivity (92%-98%) and lowest specificity (46%-54%) for consensus cervical intraepithelial neoplasia grade 3 (CIN 3). The overall accuracy of each HPV test, as measured by odds ratios, was greatest for consensus CIN-3 diagnoses, from 2- to 4-fold greater than for a less stringent precancer definition of any diagnosis of CIN 2 or more severe. In summary, there was convergence of greater certainty of carcinogenic HPV with greater certainty of a precancerous diagnosis, such that all 4 HPV tests almost always tested positive in women most likely to have cervical precancer. Finding increasingly strong associations when both test and diagnostic misclassification are reduced is a useful sign of "true association" in molecular epidemiology.

Entities:  

Mesh:

Year:  2009        PMID: 20007673      PMCID: PMC2878104          DOI: 10.1093/aje/kwp390

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  51 in total

1.  The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays.

Authors:  Mark H Stoler; Philip E Castle; Diane Solomon; Mark Schiffman
Journal:  Am J Clin Pathol       Date:  2007-03       Impact factor: 2.493

2.  Heterogeneity in CIN3 diagnosis.

Authors:  Mark Schiffman; Ana Cecilia Rodríguez
Journal:  Lancet Oncol       Date:  2008-05       Impact factor: 41.316

3.  The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report.

Authors:  Philip E Castle; Mark H Stoler; Diane Solomon; Mark Schiffman
Journal:  Am J Clin Pathol       Date:  2007-05       Impact factor: 2.493

4.  Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study.

Authors:  Philip E Castle; Patti E Gravitt; Diane Solomon; Cosette M Wheeler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

5.  Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States.

Authors:  Philip E Castle; Diane Solomon; Debbie Saslow; Mark Schiffman
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

6.  Human papillomavirus genotype specificity of hybrid capture 2.

Authors:  Philip E Castle; Diane Solomon; Cosette M Wheeler; Patti E Gravitt; Sholom Wacholder; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

7.  2006 consensus guidelines for the management of women with abnormal cervical screening tests.

Authors:  Thomas C Wright; L Stewart Massad; Charles J Dunton; Mark Spitzer; Edward J Wilkinson; Diane Solomon
Journal:  J Low Genit Tract Dis       Date:  2007-10       Impact factor: 1.925

8.  CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples.

Authors:  Joseph D Carreon; Mark E Sherman; Diego Guillén; Diane Solomon; Rolando Herrero; Jose Jerónimo; Sholom Wacholder; Ana Cecilia Rodríguez; Jorge Morales; Martha Hutchinson; Robert D Burk; Mark Schiffman
Journal:  Int J Gynecol Pathol       Date:  2007-10       Impact factor: 2.762

9.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.

Authors:  Margaret R E McCredie; Katrina J Sharples; Charlotte Paul; Judith Baranyai; Gabriele Medley; Ronald W Jones; David C G Skegg
Journal:  Lancet Oncol       Date:  2008-04-11       Impact factor: 41.316

10.  An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS).

Authors:  Philip E Castle; J Thomas Cox; Jose Jeronimo; Diane Solomon; Cosette M Wheeler; Patti E Gravitt; Mark Schiffman
Journal:  Obstet Gynecol       Date:  2008-04       Impact factor: 7.661

View more
  10 in total

1.  Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3.

Authors:  Philip E Castle; Mark Schiffman; Cosette M Wheeler; Nicolas Wentzensen; Patti E Gravitt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07       Impact factor: 4.254

2.  Using biomarkers as objective standards in the diagnosis of cervical biopsies.

Authors:  Mary T Galgano; Philip E Castle; Kristen A Atkins; William K Brix; Sarah R Nassau; Mark H Stoler
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

3.  Invited commentary: Human papillomavirus infection and risk of cervical precancer--using the right methods to answer the right questions.

Authors:  Eduardo L Franco; Joseph Tota
Journal:  Am J Epidemiol       Date:  2009-12-10       Impact factor: 4.897

4.  Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India.

Authors:  Patti E Gravitt; Proma Paul; Hormuzd A Katki; Haripriya Vendantham; Gayatri Ramakrishna; Mrudula Sudula; Basany Kalpana; Brigitte M Ronnett; K Vijayaraghavan; Keerti V Shah
Journal:  PLoS One       Date:  2010-10-28       Impact factor: 3.240

5.  Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females.

Authors:  Diane M Harper; Stephen L Vierthaler
Journal:  ISRN Obstet Gynecol       Date:  2011-11-02

6.  Molecular progression to cervical precancer, epigenetic switch or sequential model?

Authors:  Belinda Nedjai; Caroline Reuter; Amar Ahmad; Rawinder Banwait; Rhian Warman; James Carton; Sabrina Boer; Jack Cuzick; Attila T Lorincz
Journal:  Int J Cancer       Date:  2018-07-03       Impact factor: 7.396

7.  Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping.

Authors:  Rubí Hernández-López; Attila T Lorincz; Leticia Torres-Ibarra; Caroline Reuter; Dorota Scibior-Bentkowska; Rhian Warman; Belinda Nedjai; Indira Mendiola-Pastrana; Leith León-Maldonado; Berenice Rivera-Paredez; Paula Ramírez-Palacios; Eduardo Lazcano-Ponce; Jack Cuzick; Jorge Salmerón
Journal:  Clin Epigenetics       Date:  2019-10-12       Impact factor: 6.551

8.  The detection of hTERC amplification using fluorescence in situ hybridization in the diagnosis and prognosis of cervical intraepithelial neoplasia: a case control study.

Authors:  Geping Yin; Juan Li; Tongyu Zhu; Xiaoli Zhao
Journal:  World J Surg Oncol       Date:  2012-08-21       Impact factor: 2.754

9.  HPV vaccines and cancer prevention, science versus activism.

Authors:  Lucija Tomljenovic; Judy Wilyman; Eva Vanamee; Toni Bark; Christopher A Shaw
Journal:  Infect Agent Cancer       Date:  2013-02-01       Impact factor: 2.965

10.  3q26 amplification is an effective negative triage test for LSIL: a historical prospective study.

Authors:  Erica R Heitmann; Kamani M Lankachandra; Jeff Wall; George D Harris; Hollie J McKinney; G Reza Jalali; Yogita Verma; Eric Kershnar; Michael W Kilpatrick; Petros Tsipouras; Diane M Harper
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.